Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

Fig. 1

Study design. aPatients experiencing a disease flare may be rescued with open-label treatment as per Investigator’s judgment during the study treatment period. D, day; EOS, end of study; EOT, end of treatment; N, number of patients; PBO, placebo; R, randomization; SAR150/200, sarilumab 150/200 mg; V, visit; W, week

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us